AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03376009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial Spin Labelling Magnetic Resonance Imaging
Description: Magnetic resonance imaging using arterial spin labelling (ASL-MRI) This promising quantitative technique has the potential to identify dysregulated renal perfusion, stratify risk of AKI in pre-OLT patients, and to monitor alterations in renal haemodynamics in the post transplantation setting.~* We aim to recruit 5 participants with 'normal' renal function (eGFR≥60ml/min/1.73m2) and a further 5 participants with 'abnormal' renal function (eGFR\<60ml/min/1.73m2)~* ASL-MRI will be performed in this subgroup during the week of OLT assessment and then repeated at 6-weeks post transplantation in those participants who undergo OLT during the study period.
Study NCT03181009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.
Study NCT04526587 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Patient's electronic health records are reviewed
Study NCT03181009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.
Study NCT03181009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Food Flour Allergens
Description: The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.
Study NCT03181009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Food Flour Allergens
Description: The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.
Study NCT03943992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD601 40mg
Description: Patients should take druges 30 minutes before breakfast.
Study NCT03943992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 40mg
Description: Patients should take druges 30 minutes before breakfast.
Study NCT03943992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
Study NCT03943992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
Study NCT03428269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation by gaming (LabForGames Warning)
Description: comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
Study NCT03428269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional education
Description: comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
Study NCT04124510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand Name: Flutiform K-haler
Description: Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
Study NCT01346553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESVV device
Description: wearing the ESVV device for 6 hours
Study NCT02714959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin
Study NCT01168479 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FLAME boost
Description: In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
Study NCT01168479 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard arm
Description: The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
Study NCT04688996 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lateral Flow Assay for Pathogens of the Plague
Description: A dipstick type of rapid test for antigens of the plague bacterium Yersinia pestis in samples from enrolled participants from both a known geography of plague activity (Madagascar) as well as samples from a geographically separated population of likely plague free status (US Naval Health Research Center, San Diego, CA).
Study NCT02260011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide HFA-134a inhalation aerosol
Study NCT02260011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrovent® CFC inhalation aerosol
Study NCT02260011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02106208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese diet
Study NCT02106208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter diet
Study NCT02106208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO diet
Study NCT02106208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA diet
Study NCT02106208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PUFA diet
Study NCT00003018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dipyridamole
Description: 75mg/dose, PO, Days 1-28 of 5 week cycle
Study NCT00003018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 200 mg/m\^2/day, continuous IV, Days 1-28 of 5 week cycle
Study NCT00003018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 30 mg/m\^2/day, IV, Days 1,8,15,22 of 5 week cycle
Study NCT00003018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Description: 10 mg/m\^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
Study NCT04927650 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HPV testing
Description: Undergo collection of cervical samples for HPV testing
Study NCT04927650 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT01264315 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide
Description: Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients:~* absolute neutrophil count >1x109/L without growth factors~* platelet count >75x109/L without transfusion support~* calculated/measured creatinine clearance: ≥20mL/minute~* total bilirubin \<2 x the upper limit of normal~* AST (SGOT) and ALT (SGPT) \<2.5 x upper limit of normal~* \<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD~Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart.
Study NCT00919022 — intervention group
Intervention type: DRUG
Intervention: Cyproterone Acetate (Androcur, BAY94-8367)
Description: Patients in regular clinical practice receiving Androcur according to local drug information
Study NCT04163198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insufflation
Description: Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.
Study NCT04163198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exsufflation
Description: Patients will receive different exsufflation pressures at fixed insufflation pressure.
Study NCT02773628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acar'up system
Study NCT02773628 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acar'up placebo system
Study NCT02255279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)
Description: A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).
Study NCT02255279 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).
Description: A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
Study NCT04140929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Health Tool Box
Description: Please see, description of the intervention group
Study NCT00509600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 0.8 mg/kg Subcutaneously Once A Week for 90 Days
Study NCT01239745 — intervention group
Intervention type: DRUG
Intervention: Aromasin
Description: Aromasin® one 25 mg tablet to be taken once daily
Study NCT00249041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Etanercept
Description: 50 mg Etanercept liquid injected SC once weekly using prefilled syringes
Study NCT00249041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enbrel liquid
Description: 50 mg Etanercept liquid injected SC once weekly using prefilled syringes
Study NCT03004092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Twice weekly blood sample, and at every outpatient visit
Study NCT03518840 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SIJ Belt
Description: Support Belts
Study NCT00357604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)
Description: Tablets, Oral, 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 28 days.
Study NCT00357604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
Description: Tablets + Capsules/Capsules, Oral, (25 mcg of EE + 0.18/0.215/0.25 mg of NGM) + 300/100 mg then 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 21 days.
Study NCT01229553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decolonization
Description: The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
Study NCT02320825 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: single-fraction SRS
Study NCT02320825 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high-dose hypofractionated SRS
Study NCT02320825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Measures
Study NCT05160285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 100 MG in 10 ML Injection
Description: If you meet all the conditions to participate in the trial, you will receive the following treatments: Your physician will give you 360 mg of Nivolumab as an intravenous infusion every 3 weeks for about 30 minutes. For safety reasons, we recommend that you stay in the hospital for 60 minutes after the initial infusion of nivolumab. There will be a total of 3 cycles of Nivolumab treatments during the study period. You will need to return every 3 weeks. Each return will collect about 50 ml (10 tsp) of blood samples, depending on local standards.
Study NCT02898441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Computed Tomography
Description: LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm.
Study NCT00950092 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Numeris-AF Tethered Coagulation System with VisiTrax
Description: Surgical radiofrequency (RF) epicardial ablation using the nContact Numeris-AF Tethered Coagulation System
Study NCT00929097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation aids
Description: * Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids~* Clinicians receive the guidelines and a risk communication tool, as well as education
Study NCT00929097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Dissemination of guidelines
Study NCT00090402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Fish oil capsule
Study NCT00090402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish oil capsule
Study NCT00090402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipoic Acid
Description: Lipoic acid capsule
Study NCT00090402 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fish Oil Placebo
Description: Soybean oil placebo capsule
Study NCT00090402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipoic Acid Placebo
Description: Lipoic acid (LA) placebo capsule containing no LA
Study NCT00090402 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lipoic Acid Placebo
Description: Lipoic acid (LA) placebo capsule containing no LA
Study NCT01893788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Aliskiren: 150 to 300 mg daily for 48 weeks
Study NCT01893788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: 50 to 100 mg daily for 48 weeks
Study NCT01207544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitball exercise
Description: Supervised fitball exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
Study NCT01207544 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: task-oriented motor training program
Description: Task-oriented motor exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
Study NCT04244045 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suboccipital muscle inhibition
Description: The patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side; distal hand of the therapist on planter surface of foot for dorsiflexion. and proximal hand on the knee to increase the length of the muscle, maintain this stretching for 60 seconds then relax .Sub occipital muscle inhibition:~The Patient is supine, The therapist stretch the sub occipital, flexes the head of the patient to get the chin to the manibiurim sternii, maintaining this position for 60seconds then relax Slump strtch position:Patient in comfortable short sitting position at the edge of the bed with the trunk in an millitary straight position then ask the patient to slump the flex his neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot
Study NCT04244045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital muscle inhibition
Description: The patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side; distal hand of the therapist on planter surface of foot for dorsiflexion. and proximal hand on the knee to increase the length of the muscle, maintain this stretching for 60 seconds then relax .Sub occipital muscle inhibition:~The Patient is supine, The therapist stretch the sub occipital, flexes the head of the patient to get the chin to the manibiurim sternii, maintaining this position for 60seconds then relax Slump strtch position:Patient in comfortable short sitting position at the edge of the bed with the trunk in an millitary straight position then ask the patient to slump the flex his neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot
Study NCT00710970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.
Study NCT00961012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Big Squeeze
Description: Trunk release as per MSIP protocol. Standing at the foot of the bed, facing the subject, Experimenter A grasps both ends of the flat sheet to pull the trunk forward and away from the mattress surface. As the trunk release procedure is performed, Experimenter A checks to verify that the laser beam shines through to the opposite wall to confirm that the shoulders have cleared the mattress.
Study NCT03043937 — intervention group
Intervention type: OTHER
Intervention: registry
Study NCT02645708 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Retrograde Intrarenal Surgery
Description: Patients undergo Retrograde Intrarenal Surgery
Study NCT02645708 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: EPVL after RIRS
Description: Patients in Group 2 undergo EPVL after RIRS
Study NCT02677285 — intervention group
Intervention type: OTHER
Intervention: Different type of wound
Study NCT02391584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XprESS
Description: Balloon dilation of the Eustachian tube
Study NCT02391584 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Continued medical management
Study NCT01745302 — intervention group
Intervention type: DRUG
Intervention: TCM
Description: TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
Study NCT01745302 — intervention group
Intervention type: DRUG
Intervention: EGFR-TKI
Description: Erlotinib 150 mg oral once a day or Gefitinib 250 mg oral once a day or Icotinib 125 mg oral three times a day
Study NCT03548792 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: RSA radiostereometric analysis
Description: Tantalum beads will be inserted in polyethylene Component and in bone to assess micromotion of Components in radiographs
Study NCT03548792 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical comparison
Description: ActivePAL, walking speed
Study NCT02548364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol
Description: calcifediol treatment
Study NCT02548364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo control group
Study NCT00710554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Study NCT00710554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Study NCT00841074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: 0.12% chlorhexidine mouthwash spray, \~1.3 ml, twice a day.
Study NCT00841074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: Placebo mouthwash spray application of \~1.3 ml twice a day.